This Investor Sold $104 Million of Nuvalent Stock Amid Cancer Drug Developer's Nearly 30% Rally

Core Insights - Vestal Point Capital sold 1,054,000 shares of Nuvalent for an estimated $103.93 million, reflecting a significant transaction based on quarterly average pricing [1][2] - The fund's quarter-end position in Nuvalent decreased by $90.50 million, accounting for both share sales and price changes [2] Company Overview - Nuvalent is a clinical-stage biotechnology company focused on developing next-generation precision therapies for cancer, particularly addressing resistance mutations and central nervous system involvement [6] - As of February 17, 2026, Nuvalent's stock price was $102.24, with a market capitalization of $7.43 billion and a net income of -$425.4 million [4][8] - The company has experienced a one-year price change of 29.11%, outperforming the S&P 500's gain of approximately 19% during the same period [4][8] Financial Position - Nuvalent reported approximately $1.4 billion in cash and investments at the end of 2025, sufficient to fund operations into 2029 [10] - Following the sale, Nuvalent's weight in Vestal Point Capital's portfolio fell to less than 1% of 13F assets under management [8] Upcoming Developments - Nuvalent is preparing for a potential FDA decision on zidesamtinib for previously treated ROS1-positive lung cancer, with a target action date in September [8][10] - The company plans to submit another oncology candidate, neladalkib, for regulatory review in ALK-positive lung cancer [10] Product Pipeline - Nuvalent's lead candidates include NVL-520 (a ROS1-selective inhibitor) and NVL-655 (an ALK-selective inhibitor), aimed at addressing drug resistance and brain metastases in oncology [9]